Total Payments
$273,547
2024 Payments
$99,905
Companies
36
Transactions
593
Medicare Patients
5,368
Medicare Billing
$993,957
Payment Breakdown by Category
Other$198,181 (72.4%)
Consulting$38,729 (14.2%)
Travel$20,243 (7.4%)
Food & Beverage$16,287 (6.0%)
Education$106.88 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $193,831 | 77 | 70.9% |
| Consulting Fee | $38,729 | 22 | 14.2% |
| Travel and Lodging | $20,243 | 58 | 7.4% |
| Food and Beverage | $16,287 | 430 | 6.0% |
| Honoraria | $2,700 | 1 | 1.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,650 | 2 | 0.6% |
| Education | $106.88 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alnylam Pharmaceuticals Inc. | $113,636 | 145 | $0 (2024) |
| PFIZER INC. | $78,659 | 91 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $53,749 | 58 | $0 (2024) |
| Abbott Laboratories | $20,392 | 141 | $0 (2024) |
| Akcea Therapeutics, Inc. | $2,822 | 2 | $0 (2020) |
| Medtronic Vascular, Inc. | $604.95 | 5 | $0 (2019) |
| ABIOMED | $412.38 | 3 | $0 (2018) |
| Amgen Inc. | $389.55 | 23 | $0 (2023) |
| Boston Scientific Corporation | $388.54 | 6 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $381.48 | 20 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $99,905 | 163 | AstraZeneca Pharmaceuticals LP ($50,403) |
| 2023 | $45,687 | 124 | Alnylam Pharmaceuticals Inc. ($27,983) |
| 2022 | $25,943 | 91 | Alnylam Pharmaceuticals Inc. ($19,096) |
| 2021 | $41,678 | 37 | Alnylam Pharmaceuticals Inc. ($23,629) |
| 2020 | $25,134 | 25 | PFIZER INC. ($15,095) |
| 2019 | $24,845 | 61 | PFIZER INC. ($13,541) |
| 2018 | $9,567 | 52 | Abbott Laboratories ($8,532) |
| 2017 | $787.92 | 40 | Janssen Pharmaceuticals, Inc ($271.29) |
All Payment Transactions
593 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $9.12 | General |
| Category: Genetic Disease | ||||||
| 12/17/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $16.07 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,300.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/13/2024 | Tactile Systems Technology Inc | Flexitouch Plus (Device), Entre Plus | Food and Beverage | In-kind items and services | $22.13 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Travel and Lodging | In-kind items and services | $1,105.49 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $115.36 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/03/2024 | Abbott Laboratories | THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) | Food and Beverage | In-kind items and services | $3.67 | General |
| Category: Heart Failure | ||||||
| 12/02/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,763.00 | General |
| Category: Genetic Disease | ||||||
| 12/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.70 | General |
| Category: DIABETES | ||||||
| 11/27/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Consulting Fee | Cash or cash equivalent | $1,611.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/22/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $21.01 | General |
| Category: Genetic Disease | ||||||
| 11/20/2024 | PFIZER INC. | VYNDAQEL (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,000.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/19/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $22.25 | General |
| Category: Genetic Disease | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.87 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/14/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $100.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/14/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $100.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/28/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $15.64 | General |
| Category: Cardiovascular | ||||||
| 10/25/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,611.00 | General |
| 10/22/2024 | Boston Scientific Corporation | ACCOLADE SR (Device) | Food and Beverage | In-kind items and services | $80.00 | General |
| Category: ACCOLADE_CRM | ||||||
| 10/22/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $17.41 | General |
| Category: Cardiovascular | ||||||
| 10/16/2024 | Medtronic, Inc. | HAWKONE (Device) | Food and Beverage | In-kind items and services | $124.92 | General |
| Category: Directional Atherectomy Devices | ||||||
| 10/14/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $138.89 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 10/10/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $77.60 | General |
| 10/08/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $13.09 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 09/30/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.30 | General |
| Category: Cardiovascular and Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 32 | 2,234 | 3,933 | $1.4M | $478,553 |
| 2022 | 31 | 1,477 | 2,693 | $752,579 | $268,801 |
| 2021 | 17 | 875 | 1,517 | $418,054 | $127,615 |
| 2020 | 17 | 782 | 1,485 | $463,985 | $118,987 |
Total Patients
5,368
Total Services
9,628
Medicare Billing
$993,957
Procedure Codes
103
All Medicare Procedures & Services
103 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78492 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress | Office | 2023 | 82 | 82 | $266,500 | $86,905 | 32.6% |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | Office | 2023 | 103 | 104 | $206,000 | $64,440 | 31.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 296 | 527 | $76,415 | $48,469 | 63.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 123 | 449 | $78,575 | $42,966 | 54.7% |
| 78431 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | Office | 2023 | 21 | 21 | $125,925 | $40,652 | 32.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 149 | 369 | $55,350 | $23,498 | 42.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 99 | 136 | $29,240 | $18,907 | 64.7% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 106 | 424 | $50,244 | $17,928 | 35.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 190 | 216 | $104,114 | $15,032 | 14.4% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 18 | 85 | $22,695 | $14,680 | 64.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 92 | 101 | $30,300 | $14,096 | 46.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 66 | 66 | $31,416 | $11,196 | 35.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 103 | 110 | $18,370 | $11,019 | 60.0% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 44 | 48 | $21,600 | $10,513 | 48.7% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 45 | 209 | $26,648 | $8,331 | 31.3% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 43 | 185 | $23,588 | $7,239 | 30.7% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 106 | 106 | $60,950 | $5,947 | 9.8% |
| 93451 | Insertion of tube in right heart chambers for measurement | Facility | 2023 | 46 | 50 | $41,250 | $4,772 | 11.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 41 | 41 | $16,236 | $4,683 | 28.8% |
| 93264 | Remote monitoring of pulmonary artery pressure sensor, up to 30 days | Office | 2023 | 21 | 101 | $10,100 | $3,924 | 38.9% |
| 33289 | Insertion of wireless pressure sensor into lung artery through tube with review by radiologist | Facility | 2023 | 15 | 15 | $10,500 | $3,774 | 35.9% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 20 | 20 | $7,500 | $3,295 | 43.9% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 12 | 12 | $18,000 | $2,827 | 15.7% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 13 | 46 | $5,520 | $2,267 | 41.1% |
| 93505 | Biopsy of heart muscle | Facility | 2023 | 11 | 11 | $9,317 | $1,924 | 20.7% |
About Dr. Barry Trachtenberg, MD
Dr. Barry Trachtenberg, MD is a Cardiovascular Disease healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/01/2008. The National Provider Identifier (NPI) number assigned to this provider is 1639331473.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Barry Trachtenberg, MD has received a total of $273,547 in payments from pharmaceutical and medical device companies, with $99,905 received in 2024. These payments were reported across 593 transactions from 36 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($193,831).
As a Medicare-enrolled provider, Trachtenberg has provided services to 5,368 Medicare beneficiaries, totaling 9,628 services with total Medicare billing of $993,957. Data is available for 4 years (2020–2023), covering 103 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Advanced Heart Failure and Transplant Cardiology
- Location Houston, TX
- Active Since 07/01/2008
- Last Updated 10/02/2024
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1639331473
Products in Payments
- VYNDAQEL (Drug) $71,148
- ONPATTRO (Drug) $62,734
- WAINUA (Drug) $46,019
- AMVUTTRA (Drug) $43,942
- CardioMEMS HF System (Device) $11,665
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) $3,406
- VYNDAMAX (Drug) $3,092
- TEGSEDI (Drug) $2,822
- Circulatory Support (Device) $2,534
- CARDIOMEMS (Device) $1,919
- HeartMate (Device) $447.92
- Impella (Device) $412.38
- HeartWare HVAD (Device) $408.95
- XARELTO (Drug) $352.27
- Corlanor (Drug) $317.89
- ELIQUIS (Drug) $299.15
- HeartMate 3 Left Ventricular Dev (Device) $293.24
- ENTRESTO (Drug) $238.20
- CoreValve Evolut (Device) $196.00
- WATCHMAN (Device) $169.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Houston
Reynolds Delgado, M.d, M.D
Cardiovascular Disease — Payments: $600,466
Cardiovascular Disease $600,466
Dr. Miguel Valderrabano, Md, MD
Cardiovascular Disease — Payments: $471,736
Cardiovascular Disease $471,736
Asif Ali, Md, MD
Cardiovascular Disease — Payments: $461,190
Cardiovascular Disease $461,190
Mr. Mehdi Razavi, Md, MD
Cardiovascular Disease — Payments: $433,792
Cardiovascular Disease $433,792
Dr. Michele Sartori, M.d, M.D
Cardiovascular Disease — Payments: $278,682
Cardiovascular Disease $278,682
Arvind Bhimaraj, M.d.,, M.D.,
Cardiovascular Disease — Payments: $238,280
Cardiovascular Disease $238,280